Document Type : Original Research

Authors

1 Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

2 Chest Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

3 Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

4 Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

5 Histology and Cell Biology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

10.30699/ijp.2020.130944.2452

Abstract

Background and Objective: Diagnosis and discrimination of lung adenocarcinoma (LUAD) from lung squamous cell carcinoma (LUSC) is critical to select the appropriate treatment regimen as recently targeted therapies require accurate subtyping of NSCLCs. There are currently several biomarkers that could be used for differentiation between LUAD and LUSC, but they have less sensitivity, specificity, and clinical applicability. The aimof this study was to assess the diagnostic and prognostic values of CLCA2, SPATS2, ST6GALNAC1, and Adipophilin tissue expression in the tissues retrieved from LUAD and LUSC patients using immunohistochemistry.
Methods:The current study was performed on the samples retrieved from sixty primary lung masses that were diagnosed as LUAD and LUSC. Immunohistochemistry was performed by using a panel of CLCA2, SPATS2, and ST6GALNAC1. We assessed the diagnostic roles of the studied markers in the discrimination between LUAD and LUSC and their prognostic values.
Results: SPATS2 and CLCA2were expressed more in LUSC than LUAD. ST6GALNAC1 and Adipophilin were expressed more in LUAD than LUSC (p <0.001). The sensitivity and specificity of CLCA2, SPATS2, ST6GALNAC1 and Adipophilin in adequate subtyping and reaching the accurate diagnosis was 100%. We found only significant differences in survival rates between the patients with negative and positive CLCA2expression (p =0.038 and p =0.019, respectively).
Conclusions: The combination of CLCA2, SPATS2, ST6GALNAC1, and Adipophilin lead to the adequate subtyping of lung cancer and reaching accurate diagnosis with the highest sensitivity and specificity.

Keywords

Main Subjects

Zhan C, Yan L, Wang L, Sun Y, Wang X, Lin Z, Zhang Y, Shi Y, Jiang W, Wang Q. Identification of immunohistochemical markers for distinguishing lung adenocarcinoma from squamous cell carcinoma. J Thorac Dis. 2015;7(8):1398.

Takamochi K, Ohmiya H, Itoh M, Mogushi K, Saito T, Hara K, Mitani K, Kogo Y, Yamanaka Y, Kawai J, Hayashizaki Y. Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung. BMC cancer. 2016; 1;16(1):760. [DOI:10.1186/s12885-016-2792-1] [PMID] [PMCID]

Shinmura K, Igarashi H, Kato H, Kawanishi Y, Inoue Y, Nakamura S, Ogawa H, Yamashita T, Kawase A, Funai K, Sugimura H. CLCA2 as a novel immunohistochemical marker for the differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. Dis Markers. 2014. [DOI:10.1155/2014/619273] [PMID] [PMCID]

Qiang YY, Li CZ, Sun R, Zheng LS, Peng LX, Yang JP, Meng DF, Lang YH, Mei Y, Xie P, Xu L. Along with its favorable prognostic role, CLCA2 inhibits growth and metastasis of nasopharyngeal carcinoma cells via inhibition of FAK/ERK signaling. J Exp Clin Cancer Res. 2018;37(1):34. [DOI:10.1186/s13046-018-0692-8] [PMID] [PMCID]

Shin SA, Na HY, Choe JY, Chung D, Park M, Oh S, Kim JE. The expression of adipophilin is frequently found in solid subtype adenocarcinoma and is associated with adverse outcomes in lung adenocarcinoma. J Pathol Transl Med. 2018;52(6):357. [DOI:10.4132/jptm.2018.09.13] [PMID] [PMCID]

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon, France: World Health Organization Classification of Tumours, IARC; 2004.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. [DOI:10.3322/caac.21262] [PMID]

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. [DOI:10.3322/caac.20107] [PMID]

Thunnissen E, Witte BI, Nicholson AG. Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study. J Thorac Oncol. 2015;1;10(1):e4. [DOI:10.1097/JTO.0000000000000425] [PMID]

Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol. 2000; 1;53(7):537-40. [DOI:10.1136/jcp.53.7.537] [PMID] [PMCID]

Herbst RS, Heymach JV, Lippman S. Molecular origins of cancer. N Engl J Med. 2008;359(13):1367-80. [DOI:10.1056/NEJMra0802714] [PMID]

Yeh YC, Kadota K, Nitadori JI, Sima CS, Rizk NP, Jones DR, Travis WD, Adusumilli PS. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. J Cardio-Thorac Surg. 2016; 1;49(1):e9-15. [DOI:10.1093/ejcts/ezv316] [PMID] [PMCID]

Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, Garg K, Hirsch FR, Noguchi M, Powell CA, Rusch VW. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol. 2010; 1;5(4):411-4. [DOI:10.1097/JTO.0b013e3181d57f6e] [PMID]

Nagashio R, Ueda J, Ryuge S, Nakashima H, Jiang SX, Kobayashi M, Yanagita K, Katono K, Satoh Y, Masuda N, Murakumo Y. Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer. Sci Rep. 2015; 3; 5:8649. [DOI:10.1038/srep08649] [PMID] [PMCID]

Ao MH, Zhang H, Sakowski L, Sharma R, Illei PB, Gabrielson E, Askin F, Li QK. The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer. Hum Pathol. 2014; 1;45(5):926-34. [DOI:10.1016/j.humpath.2014.01.005] [PMID] [PMCID]

Khayyata S, Yun S, Pasha T, Jian B, McGrath C, Yu G, Gupta P, Baloch Z. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens. Diagn Cytopathol. 2009;37(3):178-83. [DOI:10.1002/dc.20975] [PMID]

Gruber AD, Schreur KD, Ji HL, Fuller CM, Pauli BU. Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland. Am J Physiol. 1999; 1; 276(6):C1261-70. [DOI:10.1152/ajpcell.1999.276.6.C1261] [PMID]

Elble RC, Walia V, Cheng HC, Connon CJ, Mundhenk L, Gruber AD, Pauli BU. The putative chloride channel hCLCA2 has a single C-terminal transmembrane segment. J Biol Chem. 2006; 6; 281(40):29448-54. [DOI:10.1074/jbc.M605919200] [PMID]

Yu Y, Walia V, Elble RC. Loss of CLCA4 promotes epithelial-to-mesenchymal transition in breast cancer cells. PloS One. 2013;8(12). [DOI:10.1371/journal.pone.0083943] [PMID] [PMCID]

Xing J, Tian Y, Ji W, Wang X. Comprehensive evaluation of SPATS2 expression and its prognostic potential in liver cancer. Medicine. 2020; 1; 99(9):e19230. [DOI:10.1097/MD.0000000000019230] [PMID] [PMCID]

Senoo M, Hoshino S, Mochida N, Matsumura Y, Habu S. Identification of a novel protein p59scr, which is expressed at specific stages of mouse spermatogenesis. Biochem Biophys Res Commun. 2002; 12; 292(4):992-8. [DOI:10.1006/bbrc.2002.6769] [PMID]

Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. InSeminars in cancer biology 2018; 52: (103-109). [DOI:10.1016/j.semcancer.2017.11.019] [PMID] [PMCID]

Kurosawa N, Inoue M, Yoshida Y, Tsuji S. Molecular cloning and genomic analysis of mouse Galβ1, 3GalNAc-specific GalNAc α2, 6-sialyltransferase. J Biol Chem. 1996; 21; 271(25):15109-16. [DOI:10.1074/jbc.271.25.15109] [PMID]

Kurosawa N, Takashima S, Kono M, Ikehara Y, Inoue M, Tachida Y, Narimatsu H, Tsuji S. Molecular cloning and genomic analysis of mouse GalNAc α2, 6-sialyltransferase (ST6GalNAc I). J Biochem. 2000;1;127(5):845-54. [DOI:10.1093/oxfordjournals.jbchem.a022678] [PMID]

Brockhausen I, Yang JM, Burchell J, Whitehouse C, Taylor‐Papadimitriou J. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Euro J Biochem. 1995; 233(2):607-17. [DOI:10.1111/j.1432-1033.1995.607_2.x] [PMID]

Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer: Interdisciplinary International Journal of the American Cancer Soc. 1996; 1;77(3):474-82 https://doi.org/10.1002/(SICI)1097-0142(19960201)77:33.0.CO;2-K [DOI:10.1002/(SICI)1097-0142(19960201)77:33.0.CO;2-K]

Camassei FD, Cozza R, Acquaviva A, Jenkner A, Ravà L, Gareri R, Donfrancesco A, Bosman C, Vadalà P, Hadjistilianou T, Boldrini R. Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness. Investig Ophthalmol Vis. Sci. 2003; 1;44(6):2399-403. [DOI:10.1167/iovs.02-0934] [PMID]

Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S. ATP citrate lyase: Activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 2008; 15;68(20):8547-54. [DOI:10.1158/0008-5472.CAN-08-1235] [PMID]

Luque‐García JL, Martínez‐Torrecuadrada JL, Epifano C, Cañamero M, Babel I, Casal JI. Differential protein expression on the cell surface of colorectal cancer cells associated to tumor metastasis. Proteomics. 2010;10(5):940-52. [DOI:10.1002/pmic.200900441] [PMID]

Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res. 1998; 1;294(2):309-21. [DOI:10.1007/s004410051181] [PMID]

Tolkach Y, Lüders C, Meller S, Jung K, Stephan C, Kristiansen G. Adipophilin as prognostic biomarker in clear cell renal cell carcinoma. Oncotarget. 2017; 25;8(17):28672. [DOI:10.18632/oncotarget.15639] [PMID] [PMCID]

Kohe S, Colmenero I, McConville C, Peet A. Immunohistochemical staining of lipid droplets with adipophilin in paraffin-embedded glioma tissue identifies an association between lipid droplets and tumour grade. J Histol Histopathol. 2017; 4:4. [DOI:10.7243/2055-091X-4-4]

Zhang XD, Li W, Zhang N, Hou YL, Niu ZQ, Zhong YJ, Zhang YP, Yang SY. Identification of adipophilin as a potential diagnostic tumor marker for lung adenocarcinoma. Int. J Clin Exp Med. 2014;7(4):1190.